{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:17:50Z","timestamp":1786976270534,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100014034","name":"Foundation for Research in Rheumatology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004785","name":"NordForsk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients with spondyloarthritis (SpA) using adalimumab as the main comparator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was an observational, prospective cohort study. Patients with SpA (clinical ankylosing spondylitis, nonradiographic axial SpA, or undifferentiated SpA) starting secukinumab or a TNFi during 2015\u20132018 were identified from 5 Nordic clinical rheumatology registries. Data on comorbidities and extraarticular manifestations (psoriasis, uveitis, and inflammatory bowel disease) were captured from national registries (data available in 94% of patients) and included in multivariable analyses. We assessed 1\u2010year treatment retention (crude survival curves, adjusted hazard ratios [HR\n                      <jats:sub>adj<\/jats:sub>\n                      ] for treatment discontinuation) and 6\u2010month response rates (Ankylosing Spondylitis Disease Activity Score [ASDAS] score\u2009&lt;2.1, Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] &lt;40\u2009mm, crude\/LUNDEX\u2010adjusted, adjusted logistic regression analyses with odds ratios [ORs]) stratified by line of biologic treatment (first, second, and third plus).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 10,853 treatment courses (842 secukinumab and 10,011 TNFi, of which 1,977 were adalimumab) were included. The proportions of patients treated with secukinumab during the first, second, and third\u2010plus lines of treatment were 1%, 6%, and 22%, respectively). Extraarticular manifestations varied across treatments, while other baseline characteristics were largely similar. Secukinumab had a 1\u2010year retention comparable to adalimumab as a first or second line of treatment but poorer as a third\u2010plus line of therapy (secukinumab 56% [95% confidence interval (95% CI) 51\u201361%] versus adalimumab 70% [95% CI 64\u201375%]; HR\n                      <jats:sub>adj<\/jats:sub>\n                      1.43 [95% CI 1.12\u20131.81]). Across treatment lines, secukinumab had poorer estimates for 6\u2010month response rates than adalimumab, statistically significantly only for the third\u2010plus line (adjusted analyses: ASDAS score\u2009&lt;2.1 OR 0.56 [95% CI 0.35\u20130.90]; BASDAI &lt;40\u2009mm OR 0.62 [95% CI 0.41\u20130.95]). Treatment outcomes varied across the 5 TNFi.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Secukinumab was mainly used in biologics\u2010experienced patients with SpA. Secukinumab and adalimumab performed similarly in patients who had failed a first biologic, although with increasing prior biologic exposure, adalimumab was superior.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.24523","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T14:58:59Z","timestamp":1606748339000},"page":"748-758","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["<scp>One\u2010Year<\/scp>\n                    Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses"],"prefix":"10.1002","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8931-8482","authenticated-orcid":false,"given":"Bente","family":"Glintborg","sequence":"first","affiliation":[{"name":"DANBIO and Rigshospitalet, Glostrup, Denmark, and University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2250-9348","authenticated-orcid":false,"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Di","family":"Giuseppe","sequence":"additional","affiliation":[{"name":"Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5442-902X","authenticated-orcid":false,"given":"Sella Aarrestad","family":"Provan","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[{"name":"University Hospital and University of Iceland  Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[{"name":"DANBIO and Rigshospitalet, Glostrup, Denmark, and University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital, Oslo, Norway, and S\u00f8rlandet Sykehus  Kristiansand Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan K.","family":"Wallman","sequence":"additional","affiliation":[{"name":"Lund University, Skane University Hospital  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle","family":"Aaltonen","sequence":"additional","affiliation":[{"name":"Ministry of Social Affairs and Health  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u2010Mari","family":"Hokkanen","sequence":"additional","affiliation":[{"name":"Helsinki University and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[{"name":"Helsinki University and Helsinki University Hospital  Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja Schj\u00f8dt","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka Lund","family":"Hansen","sequence":"additional","affiliation":[{"name":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arni Jon","family":"Geirsson","sequence":"additional","affiliation":[{"name":"University Hospital  Reykjavik Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine Lederballe","family":"Gr\u00f8n","sequence":"additional","affiliation":[{"name":"DANBIO and Rigshospitalet  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[{"name":"Zitelab  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[{"name":"Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Kristensen","sequence":"additional","affiliation":[{"name":"The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart T. H.","family":"Jacobsson","sequence":"additional","affiliation":[{"name":"Sahlgrenska Academy at the University of Gothenburg  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Danish Rheumatology Database (DANBIO), Anti\u2010Rheumatic Therapy in Sweden\/Swedish Rheumatology Quality (ARTIS\/SRQ), Center for Rheumatology Research (ICEBIO), Finnish Register of Biological Treatment (ROB\u2010FIN), and Norwegian Antirheumatic Drug Register (NOR\u2010DMARD) registries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210023"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41042"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S192235"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00886-7"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2018.18162"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22860"},{"issue":"78","key":"e_1_2_8_11_1","first-page":"S28","article-title":"Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities","volume":"31","author":"Yoshida K","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045872"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215934"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003060"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150389"},{"key":"e_1_2_8_16_1","first-page":"1","article-title":"Biological treatment in ankylosing spondylitis in the Nordic countries during 2010\u20132016: a collaboration between five biological registries","author":"Glintborg B","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000655"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001079"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21570"},{"key":"e_1_2_8_20_1","first-page":"10","article-title":"6 and 12\u2010month drug retention rates and treatment outcomes in 941 patients with axial spondyloarthritis treated with secukinumab in routine clinical practice in 12 European Countries in the EuroSpA Research Collaboration Network [abstract]. Arthritis","volume":"71","author":"Michelsen B","year":"2019","journal-title":"Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19858510"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04944-5"},{"key":"e_1_2_8_24_1","first-page":"438","article-title":"Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real life observational data from three Italian referral centers","volume":"20","author":"Gentileschi S","year":"2018","journal-title":"Isr Med Assoc J"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-018-0146-9"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01075-3"},{"key":"e_1_2_8_27_1","first-page":"260","article-title":"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C\u2010reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2\u2010year data from the MEASURE 2 study","volume":"37","author":"Deodhar A","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40185"},{"key":"e_1_2_8_29_1","first-page":"75","article-title":"Secukinumab in the treatment of psoriasis: patient selection and perspectives","volume":"8","author":"Yang EJ","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.234"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr.24523","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.24523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:31:54Z","timestamp":1759419114000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.24523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1002\/acr.24523"],"URL":"https:\/\/doi.org\/10.1002\/acr.24523","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"2020-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}